Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
Cancer Medicine · 2024
DOI: 10.1002/cam4.7233 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yi Zheng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospi…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myocarditis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Key Medical Discipline (Specialty) Construction Project, National Natural Science Foundation of China.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Over the past decade, immune checkpoint inhibitors (ICIs) have significantly transformed cancer treatment. However, ICIs inevitably may cause a spectrum of immune‐related adverse events, among which cardiovascular toxicity, particularly myocarditis, while infrequent, has garnered increasing attention due to its high fatality rate.
Methods
We conducted a multicenter retrospective study to characterize ICI‐associated cardiovascular adverse events. Logistic regression was performed to explore the risk factors for the development of myocarditis and severe myocarditis. Receiver operating characteristic curves were conducted to assess the diagnostic abilities of cardiac biomarkers to distinguish different cardiovascular toxicities, and the performance and calibration were evaluated using Hosmer–Lemeshow test.
Results
Forty‐four patients were identified, including thirty‐five myocarditis, five heart failure, three arrhythmias, and one myocardial infarction. Compared with other patients, myocarditis patients had higher cardiac troponin‐I (cTnI) levels ( p < 0.001), higher creatine kinase levels ( p = 0.003), higher creatine kinase isoenzyme‐MB (CK‐MB) levels ( p = 0.013), and shorter time to the incidence of adverse cardiovascular events ( p = 0.022) after ICI treatment. Twenty‐one patients (60%) were classified as severe myocarditis, and they presented higher cardiac troponin I (cTnI) levels ( p = 0.013), higher N‐terminal pro‐B‐type natriuretic peptide levels ( p = 0.031), higher creatine kinase levels ( p = 0.018), higher CK‐MB levels ( p = 0.026), and higher neutrophil to lymphocyte ratio (NLR) levels ( p = 0.016) compared to non‐severe myocarditis patients after ICI treatment. Multivariate logistic regression showed that CK‐MB (adjusted odds ratio [OR]: 1.775, 95% confidence interval [CI]: 1.055–2.984, p = 0.031) was the independent risk factor of the development of ICI‐associated myocarditis, and cTnI (adjusted OR: 1.021, 95% CI: 1.002–1.039, p = 0.03) and NLR (adjusted OR: 1.890, 95% CI: 1.026–3.483, p = 0.041) were the independent risk factors of ICI‐associated severe myocarditis. The receiver operating characteristic curve showed an area under curve of 0.785 (95% CI: 0.642 to 0.928, p = 0.013) for CK‐MB, 0.765 (95% CI: 0.601 to 0.929, p = 0.013) for cTnI, and 0.773 for NLR (95% CI: 0.597 to 0.948, p = 0.016).
Conclusions
Elevated CK‐MB after ICI treatment is the independent risk factor for the incidence of ICI‐associated myocarditis, and elevated cTnI and NLR after ICI treatment are the independent risk factors for the development of ICI‐associated severe myocarditis. CK‐MB, cTnI, and NLR demonstrated a promising predictive utility for the identification of ICI‐associated myocarditis and severe myocarditis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
- Department of Oncology, Tianjin Huanghe Hospital, Tianjin, China.
- Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.
- Department of Function, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Cardio-Oncology Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
- School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.
ORCID-Profile: Jeffrey Shi Kai Chan, Tong Liu
Förderung
- Tianjin Key Medical Discipline (Specialty) Construction Project
- National Natural Science Foundation of China
Zitieren
APA
Zheng, Y., Chen, Z., Song, W., Xu, Y., Zhao, Z., Sun, Y., Wang, Y., Geng, X., Zhao, J., Zhang, X., Xu, Y., Chan, J. S. K., Tse, G., Li, G., Hong, L., & Liu, T. (2024). Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study. Cancer Medicine. https://doi.org/10.1002/cam4.7233
Vancouver
Zheng Y, Chen Z, Song W, Xu Y, Zhao Z, Sun Y, et al. Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study. Cancer Medicine. 2024. doi:10.1002/cam4.7233
BibTeX
@article{Zheng2024,
author = {Zheng, Yi and Chen, Ziliang and Song, Wenhua and Xu, Yu and Zhao, Zhiqiang and Sun, Yihong and Wang, Yuanyuan and Geng, Xuhong and Zhao, Jun and Zhang, Xiaowei and Xu, Yanmin and Chan, Jeffrey Shi Kai and Tse, Gary and Li, Guangping and Hong, Lili and Liu, Tong},
title = {Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7233}
}
EUVIMED